{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:58:15Z","timestamp":1794473895790,"version":"4.9.1"},"reference-count":256,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005926","name":"Kose Cosmetology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"Senshin Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008670","name":"Terumo Foundation for Life Sciences and Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xphs.2023.11.001","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T12:29:51Z","timestamp":1699100991000},"page":"555-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives"],"prefix":"10.1016","volume":"113","author":[{"given":"Sherif A.","family":"Gaballa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-7574","authenticated-orcid":false,"given":"Hidenori","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2239","authenticated-orcid":false,"given":"Haruka","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-8013","authenticated-orcid":false,"given":"Sherif E.","family":"Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-1452","authenticated-orcid":false,"given":"Eslam","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef W.","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2865-145X","authenticated-orcid":false,"given":"Fatma M.","family":"Mady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-6465","authenticated-orcid":false,"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0001","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","article-title":"Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications","volume":"13","author":"D'souza","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2023.11.001_bib0002","series-title":"Engineering of Biomaterials for Drug Delivery Systems","first-page":"51","article-title":"PEGylation and anti-PEG antibodies","author":"Lila","year":"2018"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration","volume":"22","author":"Eyetech Study","year":"2002","journal-title":"J Retin"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0005","first-page":"e1485","article-title":"A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)","volume":"5","author":"Ando","year":"2022","journal-title":"Cancer Rep"},{"issue":"21","key":"10.1016\/j.xphs.2023.11.001_bib0006","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0007","first-page":"2377","article-title":"Significant FDA approvals in 2001","volume":"65","author":"McGinnis","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.xphs.2023.11.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121863","article-title":"Polymer-drug conjugates: design principles, emerging synthetic strategies and clinical overview","volume":"623","author":"Javia","year":"2022","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0009","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1021\/acs.oprd.0c00273","article-title":"Drug development through modification of small molecular drugs with monodisperse poly(ethylene glycol)s","volume":"24","author":"Wu","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0010","first-page":"1","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2010","journal-title":"J Pharm"},{"key":"10.1016\/j.xphs.2023.11.001_bib0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2020.04.026","article-title":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","volume":"152","author":"Elsadek","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2023.11.001_bib0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jconrel.2021.05.001","article-title":"Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice","volume":"334","author":"Emam","year":"2021","journal-title":"J Control Release"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0013","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0014","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/acs.molpharmaceut.0c00366","article-title":"Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in mice","volume":"17","author":"Elsadek","year":"2020","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol)(PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0017","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1248\/bpb.b13-00107","article-title":"Anti-polyethyleneglycol antibody response to PEGylated substances","volume":"36","author":"Ishida","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.xphs.2023.11.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106678","article-title":"Antibodies against polyethylene glycol in human blood: a literature review","volume":"102","author":"Hong","year":"2020","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"21","key":"10.1016\/j.xphs.2023.11.001_bib0019","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"J Anal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","article-title":"Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma","volume":"8","author":"Fang","year":"2021","journal-title":"Toxicol Rep"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0022","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","article-title":"The mystery of antibodies against polyethylene glycol (PEG)-what do we know?","volume":"33","author":"Lubich","year":"2016","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0023","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS nano"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0026","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0027","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0028","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1020134521778","article-title":"Liposome clearance","volume":"22","author":"Ishida","year":"2002","journal-title":"Biosci Rep"},{"key":"10.1016\/j.xphs.2023.11.001_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2017.01.040","article-title":"Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity","volume":"250","author":"Mima","year":"2017","journal-title":"J Control Relaese"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0032","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1021\/acs.molpharmaceut.1c00255","article-title":"Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production but not anti-DNA antibody production in mice","volume":"18","author":"Qelliny","year":"2021","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0033","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2003.12.011","article-title":"Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice","volume":"95","author":"Ishida","year":"2004","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0034","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","article-title":"Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes","volume":"105","author":"Ishida","year":"2005","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/gt.2014.32","article-title":"Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production","volume":"21","author":"Hashimoto","year":"2014","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0036","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2023.11.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121539","article-title":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes","volume":"615","author":"El Sayed","year":"2022","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0038","article-title":"The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study","volume":"7","author":"Ishida","year":"2002","journal-title":"Cell Mol Biol Lett"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0039","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2012.07.049","article-title":"Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs","volume":"436","author":"Suzuki","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2023.11.001_bib0040","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, poly (ethylene) glycol and its alternatives","volume":"114079","author":"Shi","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0041","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.xphs.2023.11.001_bib0042","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","article-title":"Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future","volume":"299","author":"Ilinskaya","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"issue":"36","key":"10.1016\/j.xphs.2023.11.001_bib0043","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0044","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jps.21808","article-title":"Effect of molecular weight, temperature, and additives on the moisture sorption properties of polyethylene glycol","volume":"99","author":"Baird","year":"2010","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5487\/TR.2015.31.2.105","article-title":"Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use","volume":"31","author":"Jang","year":"2015","journal-title":"Toxicol Res"},{"key":"10.1016\/j.xphs.2023.11.001_bib0046","doi-asserted-by":"crossref","unstructured":"Harris JM 1992. Introduction to biotechnical and biomedical applications of poly (ethylene glycol). 1-14. https:\/\/doi.org\/10.1007\/978-1-4899-0703-5_1.","DOI":"10.1007\/978-1-4899-0703-5_1"},{"key":"10.1016\/j.xphs.2023.11.001_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112669","article-title":"A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum","volume":"474","author":"Ehlinger","year":"2019","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0048","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0939-6411(98)00038-1","article-title":"Surface-modified biodegradable albumin nano-and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats","volume":"46","author":"Roser","year":"1998","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2005.06.001","article-title":"Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products","volume":"214","author":"Fruijtier-P\u00f6lloth","year":"2005","journal-title":"Toxicol"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0051","first-page":"710","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"STAM"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0052","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J"},{"issue":"10","key":"10.1016\/j.xphs.2023.11.001_bib0053","first-page":"281","article-title":"Some pharmacological properties of polyethylene glycols of high molecular weight (\u201ccarbowax\u201d compounds)","volume":"24","author":"Smyth","year":"1942","journal-title":"J Ind Hyg Toxicol"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0054","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-5173(99)00388-9","article-title":"Unexpected skin barrier influence from nonionic emulsifiers","volume":"195","author":"B\u00e1r\u00e1ny","year":"2000","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0041-008X(82)90016-3","article-title":"Toxicity of topical polyethylene glycol","volume":"65","author":"Herold","year":"1982","journal-title":"Toxicol Appl"},{"key":"10.1016\/j.xphs.2023.11.001_bib0056","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0057","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/nutrit\/nuaa038","article-title":"Food additive emulsifiers: a review of their role in foods, legislation and classifications, presence in food supply, dietary exposure, and safety assessment","volume":"79","author":"Cox","year":"2021","journal-title":"Nutr Rev"},{"issue":"1119","key":"10.1016\/j.xphs.2023.11.001_bib0058","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1039\/an9699400481","article-title":"The determination of polyoxyethylene emulsifiers in foods","volume":"94","author":"Murphy","year":"1969","journal-title":"Anal"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0059","first-page":"e05293","article-title":"Refined exposure assessment of polyethylene glycol (E 1521) from its use as a food additive","volume":"16","author":"Younes","year":"2018","journal-title":"EFSA J"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/cea.13822","article-title":"Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients","volume":"51","author":"Bruusgaard-Mouritsen","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0061","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/adc.2005.072918","article-title":"Is polyethylene glycol safe and effective for chronic constipation in children?","volume":"90","author":"Arora","year":"2005","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0062","doi-asserted-by":"crossref","first-page":"305","DOI":"10.14309\/ajg.0000000000000057","article-title":"Comparing the real-world effectiveness of competing colonoscopy preparations: results of a prospective trial","volume":"114","author":"Gu","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0016-5107(96)70259-6","article-title":"Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison","volume":"43","author":"Clarkston","year":"1996","journal-title":"Gastrointest Endosc"},{"issue":"8-9","key":"10.1016\/j.xphs.2023.11.001_bib0064","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.progpolymsci.2007.05.008","article-title":"Polymer\u2013drug conjugation, recent achievements and general strategies","volume":"32","author":"Pasut","year":"2007","journal-title":"Prog Polym Sci"},{"issue":"12","key":"10.1016\/j.xphs.2023.11.001_bib0065","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0066","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0067","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cbpa.2010.06.175","article-title":"Design of next-generation protein therapeutics","volume":"14","author":"Caravella","year":"2010","journal-title":"Curr Res Chem Biol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0068","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0069","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jev\u0161evar","year":"2010","journal-title":"Biotechnol J"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0071","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation","volume":"40","author":"Harris","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"1-3","key":"10.1016\/j.xphs.2023.11.001_bib0072","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0168-3659(01)00277-2","article-title":"Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C","volume":"72","author":"Kozlowski","year":"2001","journal-title":"J Control Release"},{"issue":"16","key":"10.1016\/j.xphs.2023.11.001_bib0073","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/hmg\/10.16.1639","article-title":"Enzyme therapy for lysosomal acid lipase deficiency in the mouse","volume":"10","author":"Du","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0074","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2007.11.030","article-title":"The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats","volume":"353","author":"Dadashzadeh","year":"2008","journal-title":"Int J Pharm"},{"issue":"24","key":"10.1016\/j.xphs.2023.11.001_bib0075","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1016\/j.biomaterials.2006.03.039","article-title":"Parameters influencing the stealthiness of colloidal drug delivery systems","volume":"27","author":"Vonarbourg","year":"2006","journal-title":"J Biomater"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0076","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1166\/jbn.2008.021","article-title":"PEGylation of nanocarrier drug delivery systems: state of the art","volume":"4","author":"Howard","year":"2008","journal-title":"J Biomed Nanotechnol"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0077","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-200115070-00001","article-title":"Development of pegylated interferons for the treatment of chronic hepatitis C","volume":"15","author":"Kozlowski","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.xphs.2023.11.001_bib0078","series-title":"Enzyme Engineering: Volume 4","first-page":"169","article-title":"Enzyme-polyethylene glycol adducts: modified enzymes with unique properties","author":"Davis","year":"1978"},{"issue":"2-3","key":"10.1016\/j.xphs.2023.11.001_bib0079","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0169-409X(95)00023-Z","article-title":"Chemistry of polyethylene glycol conjugates with biologically active molecules","volume":"16","author":"Zalipsky","year":"1995","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/bc00031a006","article-title":"A branched monomethoxypoly (ethylene glycol) for protein modification","volume":"6","author":"Monfardini","year":"1995","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0081","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/088391159701200303","article-title":"Branched and linear poly (ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates","volume":"12","author":"Veronese","year":"1997","journal-title":"J Bioact Compat Polym"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0082","first-page":"S228","article-title":"PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years","volume":"76","author":"Hershfield","year":"1995","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0083","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/104345429501200110","article-title":"Pegaspargase (oncaspar)","volume":"12","author":"Ettinger","year":"1995","journal-title":"J Pediatr Oncol Nurs"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0084","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0958-1669(03)00092-2","article-title":"The enzyme as drug: application of enzymes as pharmaceuticals","volume":"14","author":"Vellard","year":"2003","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/106002809703100517","article-title":"Pegaspargase: an alternative?","volume":"31","author":"Holle","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.xphs.2023.11.001_bib0086","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.04.007","article-title":"Aptamer chemistry","volume":"134","author":"R\u00f6thlisberger","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0087","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0088","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tibtech.2011.03.001","article-title":"Cancer theranostics: the rise of targeted magnetic nanoparticles","volume":"29","author":"Cole","year":"2011","journal-title":"Trends Biotechnol"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0089","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1242\/jcs.115.4.849","article-title":"Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target","volume":"115","author":"Beningo","year":"2002","journal-title":"J Cell Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2007.11.009","article-title":"The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats","volume":"126","author":"Ishida","year":"2008","journal-title":"J control release"},{"issue":"12_Part_1","key":"10.1016\/j.xphs.2023.11.001_bib0091","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0092","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0005-2736(91)90162-2","article-title":"Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times","volume":"1070","author":"Lasic","year":"1991","journal-title":"Biochim Biophys Acta Bioenerg"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0093","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0005-2736(90)90440-Y","article-title":"Liposomes for the sustained drug release in vivo","volume":"1029","author":"Blume","year":"1990","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.xphs.2023.11.001_bib0094","series-title":"Cancer Nanotechnology","first-page":"25","article-title":"Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting","author":"Greish","year":"2010"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc100070g","article-title":"Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects","volume":"21","author":"Maeda","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.xphs.2023.11.001_bib0096","series-title":"Development of Pharmaceutical Nanomedicines","first-page":"6","author":"James","year":"1995"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0097","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"EJC"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0098","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0099","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/mthe.2002.0568","article-title":"Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation","volume":"5","author":"Oupicky","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.xphs.2023.11.001_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biomaterials.2014.10.036","article-title":"Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers","volume":"38","author":"Miteva","year":"2015","journal-title":"J Biomater"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0101","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2023.11.001_bib0102","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/B978-0-12-800148-6.00002-X","article-title":"Lipid nanoparticles for gene delivery","volume":"88","author":"Zhao","year":"2014","journal-title":"Adv Genet"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0103","first-page":"1068","article-title":"The importance of poly (Ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles","volume":"12","author":"Zukancic","year":"2020","journal-title":"J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2023.11.001_bib0104","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0105","doi-asserted-by":"crossref","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Chand M, Brown K, Ladhani S 2021. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv. https:\/\/doi.org\/10.1101\/2021.09.15.21263583.","DOI":"10.1101\/2021.09.15.21263583"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0106","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41591-021-01316-7","article-title":"Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine","volume":"27","author":"Levine-Tiefenbrun","year":"2021","journal-title":"J Nat Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0107","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"JPET"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0109","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)29419-2","article-title":"Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection","volume":"298","author":"Laverman","year":"2001","journal-title":"JPET"},{"issue":"23","key":"10.1016\/j.xphs.2023.11.001_bib0110","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(03)00085-1","article-title":"Accelerated clearance of a second injection of PEGylated liposomes in mice","volume":"255","author":"Ishida","year":"2003","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0112","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0113","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0114","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.xphs.2023.11.001_bib0115","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"147","article-title":"The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)","author":"Armstrong","year":"2009"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0116","first-page":"1","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"JART"},{"key":"10.1016\/j.xphs.2023.11.001_bib0117","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0118","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1002\/jps.22682","article-title":"Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance","volume":"100","author":"Kaminskas","year":"2011","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13318-021-00741-w","article-title":"Impact of antibodies against polyethylene glycol on the pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukaemia: a population pharmacokinetic approach","volume":"47","author":"Siebel","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2023.11.001_bib0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly (ethylene glycol) adversel y affects PEG-asparaginase therapy in acute lymphoblastic leukemi a patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"J Cancer"},{"issue":"12","key":"10.1016\/j.xphs.2023.11.001_bib0121","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov Today"},{"issue":"42","key":"10.1016\/j.xphs.2023.11.001_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.08.024","article-title":"mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations","volume":"40","author":"Carre\u00f1o","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2023.11.001_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0124","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"issue":"16","key":"10.1016\/j.xphs.2023.11.001_bib0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168838","article-title":"Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration","volume":"23","author":"Guerrini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xphs.2023.11.001_bib0126","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2023.11.001_bib0127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2018.08.022","article-title":"Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo","volume":"287","author":"Grenier","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2023.11.001_bib0128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.104.078113","article-title":"Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid","volume":"312","author":"Semple","year":"2005","journal-title":"JPET"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0130","first-page":"53","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"TIPS"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.151.4.853","article-title":"Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency","volume":"151","author":"Slack","year":"1980","journal-title":"Exp Med"},{"key":"10.1016\/j.xphs.2023.11.001_bib0132","series-title":"Janeway's immuno biology","author":"Janeway","year":"2008"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0133","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0952-7915(95)80109-X","article-title":"T cell independent antigens","volume":"7","author":"Mond","year":"1995","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0134","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.iy.13.040195.003255","article-title":"T cell-independent antigens type 2","volume":"13","author":"Mond","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J control release"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0136","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1365-2249.2002.01953.x","article-title":"The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens","volume":"130","author":"Zandvoort","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0137","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1248\/bpb.b20-00345","article-title":"Pegfilgrastim (PEG-G-CSF) Induces anti-polyethylene glycol (PEG) IgM via a T cell-dependent mechanism","volume":"43","author":"Elsadek","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.xphs.2023.11.001_bib0138","series-title":"Encyclopedia of Immunology","first-page":"825","article-title":"Epitopes","author":"Liang","year":"1998"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0139","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses: cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"J Cell"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1600-0854.2009.00913.x","article-title":"Dynamics of membrane trafficking downstream of B and T cell receptor engagement: impact on immune synapses","volume":"10","author":"Yuseff","year":"2009","journal-title":"Traffic"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0141","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0142","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2012.11.016","article-title":"Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon","volume":"165","author":"Shiraishi","year":"2013","journal-title":"J control release"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0143","first-page":"324","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"STAM"},{"key":"10.1016\/j.xphs.2023.11.001_bib0144","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2018.02.019","article-title":"A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes","volume":"127","author":"Shimizu","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2008.06.004","article-title":"Particle size-dependent triggering of accelerated blood clearance phenomenon","volume":"362","author":"Koide","year":"2008","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0146","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijpharm.2012.11.015","article-title":"Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application","volume":"441","author":"Nagao","year":"2013","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0147","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.09.047","article-title":"Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin","volume":"476","author":"Suzuki","year":"2014","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0148","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1515\/ntrev-2012-0040","article-title":"Immune responses of therapeutic lipid nanoparticles","volume":"2","author":"Chen","year":"2013","journal-title":"Nanotechnol Rev"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2009.10.017","article-title":"CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes","volume":"142","author":"Tagami","year":"2010","journal-title":"J Control Release"},{"issue":"6813","key":"10.1016\/j.xphs.2023.11.001_bib0150","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"J Nat"},{"key":"10.1016\/j.xphs.2023.11.001_bib0151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.04.003","article-title":"B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice","volume":"184","author":"Hashimoto","year":"2014","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0152","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2010.12.013","article-title":"Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA","volume":"151","author":"Tagami","year":"2011","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0153","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0154","first-page":"1363","article-title":"Subvisible particles derived by dropping stress enhance anti-PEG antibody production and clearance of PEGylated proteins in mice","volume":"111","author":"Nakajima","year":"2022","journal-title":"J Pharm Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0155","first-page":"521","article-title":"Synergistic effect of cavitation and agitation on protein aggregation","volume":"106","author":"Torisu","year":"2017","journal-title":"J Pharm Pharm"},{"key":"10.1016\/j.xphs.2023.11.001_bib0156","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jconrel.2021.01.015","article-title":"Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice","volume":"331","author":"Sylvestre","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0157","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1398-9995.1981.tb01830.x","article-title":"Antigenic, adjuvant and permeability enhancing properties of melittin in mice","volume":"36","author":"Kind","year":"1981","journal-title":"Allergy"},{"issue":"8-10","key":"10.1016\/j.xphs.2023.11.001_bib0158","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/10611860410001670080","article-title":"Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids","volume":"11","author":"Bramwell","year":"2003","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0159","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.4049\/jimmunol.153.3.1124","article-title":"Structure-immunogenicity relationship of melittin, its transposed analogues, and D-melittin","volume":"153","author":"King","year":"1994","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0160","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1529\/biophysj.106.095208","article-title":"Molecular analysis of TCR and peptide\/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution","volume":"92","author":"Nakagawa","year":"2007","journal-title":"Biophys J"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0161","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1096\/fasebj.11.6.9194525","article-title":"Different roles of D-amino acids in immune phenomena","volume":"11","author":"Seia","year":"1997","journal-title":"FASEB J"},{"issue":"52","key":"10.1016\/j.xphs.2023.11.001_bib0162","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0168-8278(10)60309-1","article-title":"307 High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon","author":"Tillmann","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0163","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0164","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0166","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/molecules23071700","article-title":"Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro","volume":"23","author":"Neun","year":"2018","journal-title":"J Mol"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0167","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0168","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/10717544.2014.885998","article-title":"Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection","volume":"22","author":"Xu","year":"2015","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0169","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2006.11.015","article-title":"Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle","volume":"118","author":"Lu","year":"2007","journal-title":"J control release"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2012.04.049","article-title":"Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles","volume":"432","author":"Koide","year":"2012","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2023.11.001_bib0171","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2008.06.012","article-title":"Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria","volume":"362","author":"Joshi","year":"2008","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0172","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","article-title":"Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties","volume":"3","author":"Besin","year":"2019","journal-title":"Immunohorizons"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0173","first-page":"725","article-title":"Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon","volume":"218","author":"Shimizu","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0174","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jconrel.2022.12.005","article-title":"The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes","volume":"353","author":"Grenier","year":"2023","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0175","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejpb.2012.04.023","article-title":"A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats","volume":"81","author":"Zhao","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2023.11.001_bib0176","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2023.06.027","article-title":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","volume":"360","author":"Takata","year":"2023","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.xphs.2023.11.001_bib0177","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1002\/jps.23254","article-title":"Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species","volume":"101","author":"Li","year":"2012","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0178","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0179","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clinthera.2015.03.001","article-title":"New FDA-approved disease-modifying therapies for multiple sclerosis","volume":"37","author":"English","year":"2015","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.xphs.2023.11.001_bib0181","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.131202998","article-title":"How the immune system works to protect the host from infection: a personal view","volume":"98","author":"Janeway","year":"2001","journal-title":"PNAS"},{"issue":"10","key":"10.1016\/j.xphs.2023.11.001_bib0182","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"J Immunobiol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0183","first-page":"1257","article-title":"Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy","volume":"8","author":"Yang","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0184","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.bi.50.070181.002245","article-title":"The proteolytic activation systems of complement","volume":"50","author":"Reid","year":"1981","journal-title":"Annu Rev Biochem"},{"issue":"10","key":"10.1016\/j.xphs.2023.11.001_bib0185","first-page":"1225","article-title":"Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs","volume":"41","author":"Bradley","year":"2001","journal-title":"J Blood Transfus"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0186","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0187","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/156720105774370212","article-title":"Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins","volume":"2","author":"Szebeni","year":"2005","journal-title":"Curr Drug Deliv"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0188","doi-asserted-by":"crossref","first-page":"H1050","DOI":"10.1152\/ajpheart.00622.2005","article-title":"Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function","volume":"290","author":"Szebeni","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0189","doi-asserted-by":"crossref","first-page":"H1319","DOI":"10.1152\/ajpheart.2000.279.3.H1319","article-title":"Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction","volume":"279","author":"Szebeni","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine: NBM"},{"issue":"12","key":"10.1016\/j.xphs.2023.11.001_bib0191","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2023.11.001_bib0192","first-page":"79","article-title":"Complement activation-related pseudo allergy of PEGylated products: Safety aspects, models, the role of anti-PEG antibodies, and ways to overcome","author":"Mohamed","year":"2022","journal-title":"JABPS"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0193","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/10611860008997901","article-title":"Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease","volume":"8","author":"Brouwers","year":"2000","journal-title":"J Drug Target"},{"issue":"2-3","key":"10.1016\/j.xphs.2023.11.001_bib0194","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"J Toxicol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2021.12.033","article-title":"Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists","volume":"342","author":"Stavnsbjerg","year":"2022","journal-title":"J control release"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0196","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti\u2013polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0197","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00001813-199801000-00005","article-title":"Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)","volume":"9","author":"Skubitz","year":"1998","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0198","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0199","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41565-021-01001-3","article-title":"The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines","volume":"16","author":"Bigini","year":"2021","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0200","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.xphs.2023.11.001_bib0201","doi-asserted-by":"crossref","unstructured":"Kozma GT, Meszaros T, Berenyi P, Facsko R, Patko Z, Olah CZ, Nagy A, Fulop TG, Glatter KA, Radovits T 2022. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions and immunogenicity of PEG-containing Covid-19 vaccines. medRxiv.2022-2010. https:\/\/doi.org\/10.1101\/2022.10.03.22280227.","DOI":"10.1101\/2022.10.03.22280227"},{"key":"10.1016\/j.xphs.2023.11.001_bib0202","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Senti","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2023.11.001_bib0203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0204","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jconrel.2012.02.029","article-title":"Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model","volume":"160","author":"Szebeni","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2023.11.001_bib0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0206","first-page":"313","article-title":"Physiology of gangliosides and the role of antiganglioside antibodies in human diseases","volume":"17","author":"Cutillo","year":"2020","journal-title":"CMI"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0207","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1084\/jem.20091873","article-title":"Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo","volume":"207","author":"Duong","year":"2010","journal-title":"Exp Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0208","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2008.05.009","article-title":"Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives","volume":"130","author":"Xu","year":"2008","journal-title":"J Control Release"},{"issue":"17","key":"10.1016\/j.xphs.2023.11.001_bib0209","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.biomaterials.2010.02.049","article-title":"Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes","volume":"31","author":"Xu","year":"2010","journal-title":"Biomater"},{"key":"10.1016\/j.xphs.2023.11.001_bib0210","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2147\/IJN.S24344","article-title":"Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon","volume":"6","author":"Chen","year":"2011","journal-title":"Int J Nanomed"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0211","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/bc200049d","article-title":"Polyoxazoline: chemistry, properties, and applications in drug delivery","volume":"22","author":"Viegas","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.xphs.2023.11.001_bib0212","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.eurpolymj.2016.10.041","article-title":"POxylation as an alternative stealth coating for biomedical applications","volume":"88","author":"Bludau","year":"2017","journal-title":"Eur Polym J"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0213","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/mp300496x","article-title":"Conjugates of superoxide dismutase 1 with amphiphilic poly (2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo","volume":"10","author":"Tong","year":"2013","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0214","first-page":"703","article-title":"Biocompatibility testing of branched and linear polyglycidol","volume":"7","author":"Kainthan","year":"2006","journal-title":"Biol Macromol"},{"issue":"35","key":"10.1016\/j.xphs.2023.11.001_bib0215","doi-asserted-by":"crossref","first-page":"9135","DOI":"10.1016\/j.biomaterials.2012.09.007","article-title":"Influence of architecture of high molecular weight linear and branched polyglycerols on their biocompatibility and biodistribution","volume":"33","author":"Imran ul-haq","year":"2012","journal-title":"Biomater"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0216","first-page":"1406","article-title":"Polyglycerol for half-life extension of proteins\u2014alternative to PEGylation?","volume":"22","author":"Tully","year":"2021","journal-title":"Biol Macromol"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0217","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2013.07.059","article-title":"Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration","volume":"456","author":"Lila","year":"2013","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0218","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/jps.23823","article-title":"Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery","volume":"103","author":"Lila","year":"2014","journal-title":"J Pharm Sci"},{"issue":"46","key":"10.1016\/j.xphs.2023.11.001_bib0219","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.1002\/ange.200803570","article-title":"A switchable biocompatible polymer surface with self-sterilizing and nonfouling capabilities","volume":"120","author":"Cheng","year":"2008","journal-title":"Angew Chem"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0220","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/adma.200901407","article-title":"Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications","volume":"22","author":"Jiang","year":"2010","journal-title":"Adv Mater"},{"issue":"18","key":"10.1016\/j.xphs.2023.11.001_bib0221","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1021\/la8013046","article-title":"Molecular simulation studies of protein interactions with zwitterionic phosphorylcholine self-assembled monolayers in the presence of water","volume":"24","author":"He","year":"2008","journal-title":"LANGD5"},{"issue":"39","key":"10.1016\/j.xphs.2023.11.001_bib0222","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1512465112","article-title":"Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity","volume":"112","author":"Zhang","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.xphs.2023.11.001_bib0223","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119521","article-title":"Blood retention and antigenicity of polycarboxybetaine-modified liposomes","volume":"586","author":"Ryujin","year":"2020","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0224","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.xphs.2020.01.019","article-title":"The use of lactose as an alternative coating for nanoparticles","volume":"109","author":"Betker","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/glycob\/cwv008","article-title":"Properties and functions of lactosylceramide from mouse neutrophils","volume":"25","author":"Iwabuchi","year":"2015","journal-title":"Glycobiol"},{"key":"10.1016\/j.xphs.2023.11.001_bib0226","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cocis.2017.06.004","article-title":"PASylation\u00ae: a versatile technology to extend drug delivery","volume":"31","author":"Binder","year":"2017","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0227","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.xphs.2023.11.001_bib0228","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10930-017-9699-9","article-title":"Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties","volume":"36","author":"Hedayati","year":"2017","journal-title":"Protein J"},{"key":"10.1016\/j.xphs.2023.11.001_bib0229","article-title":"Few novel antibiotics in the pipeline","volume":"358","author":"Kmietowicz","year":"2017","journal-title":"WHO Warns"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0230","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1109\/TEM.2013.2257792","article-title":"R&D intensity and the new product development portfolio","volume":"60","author":"Chao","year":"2013","journal-title":"IEEE Trans Eng Manag"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0231","first-page":"113","article-title":"General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires","volume":"15","author":"Soshee","year":"2014","journal-title":"Biol Macromol"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0232","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/acsbiomaterials.7b00147","article-title":"Cross-reactivity of select PEG-binding antibodies to other polymers containing a CCO backbone","volume":"3","author":"McCallen","year":"2017","journal-title":"ACS Biomater Sci Eng"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0233","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801177","article-title":"Architectural modification of conformal PEG-bottlebrush coatings minimizes anti-PEG antigenicity while preserving stealth properties","volume":"8","author":"Joh","year":"2019","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0234","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1039\/C4CS00329B","article-title":"Structure, function, self-assembly, and applications of bottlebrush copolymers","volume":"44","author":"Verduzco","year":"2015","journal-title":"Chem Soc Rev"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0002","article-title":"A brush-polymer\/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly (ethylene glycol) antigenicity","volume":"1","author":"Qi","year":"2016","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0236","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0019","article-title":"Drug delivery: brushing off antigenicity","volume":"1","author":"Lee","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.xphs.2023.11.001_bib0237","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121415","article-title":"Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy","volume":"283","author":"Liu","year":"2022","journal-title":"Biomater"},{"issue":"11","key":"10.1016\/j.xphs.2023.11.001_bib0238","first-page":"1530","article-title":"Pegasys (Hoffmann-La Roche)","volume":"2","author":"Barnard","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0239","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2007.04.017","article-title":"Formulation of Neulasta\u00ae(pegfilgrastim)","volume":"60","author":"Piedmonte","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"15","key":"10.1016\/j.xphs.2023.11.001_bib0240","first-page":"12","article-title":"Drug profile: Somavert","volume":"2","author":"Yang","year":"2009","journal-title":"Discov Med"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0241","first-page":"954","article-title":"A high-throughput test to detect CERA doping in blood","volume":"50","author":"Lamon","year":"2009","journal-title":"JPBA"},{"issue":"8","key":"10.1016\/j.xphs.2023.11.001_bib0242","doi-asserted-by":"crossref","DOI":"10.1038\/nrd2654","article-title":"Certolizumab pegol","volume":"7","author":"Melmed","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0243","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0244","first-page":"17","article-title":"FDA approval of Omontys changes the ESA playing field","volume":"26","author":"Neumann","year":"2012","journal-title":"Nephrol News Issues"},{"issue":"6","key":"10.1016\/j.xphs.2023.11.001_bib0245","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1345\/aph.1Q791","article-title":"Sylatron: a pegylated interferon for use in melanoma","volume":"46","author":"Patel","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.xphs.2023.11.001_bib0246","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hae.13807","article-title":"Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial","volume":"25","author":"Gruppo","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0247","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/pharmaceutics14010106","article-title":"Development of pharmaceutical nanomedicines: from the bench to the market","volume":"14","author":"Halwani","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.xphs.2023.11.001_bib0248","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40259-018-0292-3","article-title":"Pegvaliase: first global approval","volume":"32","author":"Markham","year":"2018","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.xphs.2023.11.001_bib0249","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: Calaspargase Pegol-mknl For treatment of acute lymphoblastic leukemia in children and young adults FDA approval summary: Calaspargase Pegol-mknl","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xphs.2023.11.001_bib0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.08.023","article-title":"Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial","volume":"183","author":"Santagostino","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.11.001_bib0251","article-title":"Extended Half-life rFVIII for the treatment of hemophilia a: drugs consumption and patients\u2019 perspective","volume":"21","author":"Roggeri","year":"2020","journal-title":"Farmeconomia"},{"issue":"9","key":"10.1016\/j.xphs.2023.11.001_bib0252","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2174\/1389450123666220408101152","article-title":"Pegfilgrastim-Apgf (Nyvepria): biosimilar USFDA approval for the treatment of chemotherapy-induced febrile neutropenia and current updates on clinical trials","volume":"23","author":"Ali","year":"2022","journal-title":"Curr Drug Targets"},{"issue":"12","key":"10.1016\/j.xphs.2023.11.001_bib0253","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2023.11.001_bib0254","first-page":"1","article-title":"Lonapegsomatropin: pediatric first approval","author":"Lamb","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.xphs.2023.11.001_bib0255","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14737140.2016.1192471","article-title":"The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy","volume":"16","author":"Passero","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.xphs.2023.11.001_bib0256","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vascn.2011.07.003","article-title":"A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers","volume":"64","author":"Liu","year":"2011","journal-title":"J Pharmacol Toxicol Methods"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:46:31Z","timestamp":1758361591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923004720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":256,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0022354923004720"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.11.001","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}